Pomalidomide Enhanced Antitumor Effect of Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer Cells

被引：0
|
作者：
Saito, Nobuhiro [1 ]
Shirai, Yoshihiro [1 ]
Sugano, Hiroshi [1 ]
Horiuchi, Takashi [1 ]
Iwase, Ryota [1 ]
Haruki, Koichiro [1 ]
Shiba, Hiroaki [1 ]
Uwagawa, Tadashi [1 ]
Ohashi, Toya [1 ]
Yanaga, Katsuhiko [1 ]
机构：
[1] Jikei Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS | 2016年 / 223卷 / 04期
关键词：
D O I：
10.1016/j.jamcollsurg.2016.08.365
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：E142 / E142
页数：1
相关论文
共 50 条
  • [41] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
    Drengler, R. L.
    Smith, L. S.
    Wood, T. E.
    Borad, M. J.
    Ramanathan, R. K.
    Laheru, D. A.
    Hidalgo, M.
    Von Hoff, D. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
    Lee, S. J.
    Oh, D-Y.
    Kang, J-H.
    Choi, H. J.
    Lee, M. A.
    Oh, S. Y.
    Kim, S-T.
    Park, Y. S.
    Ryu, B-Y.
    Park, J. O.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [43] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
    Matsumoto, Toshihiko
    Kurioka, Yusuke
    Okazaki, Ukyo
    Matsuo, Yu
    Kimura, Shogo
    Miura, Kou
    Tsuduki, Takao
    Takagi, Shinjiro
    Takatani, Masahiro
    Morishita, Hirofumi
    [J]. PANCREAS, 2020, 49 (04) : 574 - 578
  • [44] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [45] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [46] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    [J]. Journal of Hematology & Oncology, 16
  • [47] Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer
    Kawaida, Hiromichi
    Kono, Hiroshi
    Amemiya, Hidetake
    Saitou, Ryou
    Yamamoto, Atsushi
    Hosomura, Naohiro
    Watanabe, Mitsuaki
    Kimura, Ayako
    Furuya, Shinji
    Shimizu, Hiroki
    Akaike, Hidenori
    Kawaguchi, Yoshihiko
    Sudo, Makoto
    Itakura, Jun
    Hayakawa, Hiroshi
    Shindo, Hiroko
    Takahashi, Ei
    Takano, Shinichi
    Fukasawa, Mitsuharu
    Ichikawa, Shintaro
    Fujii, Hideki
    Ichikawa, Daisuke
    [J]. ANTICANCER RESEARCH, 2018, 38 (11) : 6537 - 6542
  • [48] A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel
    Morelli, C.
    Formica, V.
    Nardecchia, A.
    Lucchetti, J.
    Tisone, G.
    Anselmo, A.
    Blanco, C. Del Vecchio
    Benassi, M.
    Palmieri, G.
    Argiro, R.
    Roselli, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [49] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
    Hakon Blomstrand
    Ursula Scheibling
    Charlotte Bratthäll
    Henrik Green
    Nils O. Elander
    [J]. BMC Cancer, 19
  • [50] Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer
    Perez, Kimberly
    Weekes, Colin D.
    Cleary, James M.
    Abrams, Thomas Adam
    Blaszkowsky, Lawrence Scott
    Enzinger, Peter C.
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas Adam
    Yurgelun, Matthew B.
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason
    Aguirre, Andrew
    Needle, Michael N.
    Rustgi, Anil
    Wolpin, Brian M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345